Vancouver, British Columbia – TheNewswire – November 11, 2021. Lexston Life Sciences Corp. (CSE:LEXT) (CNSX:LEXT.CN) (“Lexston”) granted 1,400,000 stock options to its directors, officers, consultants and employees.
Each stock option is exercisable at $0.135 per share. The options vest immediately and expire on November 11, 2026.
All options were granted pursuant to the 10% rolling stock option plan of Lexston dated January 15, 2021 (the “Plan”).
As of the date of this news release Lexston has 5,680,000 stock options granted and 23,363 stock options available for future grants.
About Lexston Life Sciences Corp.
Lexston Life Sciences Corp. is a Canadian biotechnology company providing cannabis testing and research services. Lexston is also in the process of securing licensing under the exemptions prescribed by section 56 of the Controlled Drugs and Substances Act (Canada) to enable the expansion of its services into the psychedelic industry with an initial focus on the detection and quantification of psychedelic molecules in the lab and point of care. Lexston intends to develop and validate methods for standardized manufacturing of plant derived psychedelics in support of burgeoning trials in the field of mental health and wellness.
On Behalf of the Board of Directors
LEXSTON LIFE SCIENCES CORP.
Jagdip Bal Chief Executive Officer
Telephone: (604) 928-8913
Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
Copyright (c) 2021 TheNewswire – All rights reserved.
